v3.26.1
Stockholders’ Equity (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders’ Equity [Abstract]  
Schedule of Changes in Options

A summary of the changes in options during the three months ended March 31, 2026 is as follows:

 

   Number of
Options		   Weighted
Average
Exercise
Price
Per
Share		   Weighted
Average
Remaining
Contractual
Term
(Years)		   Aggregate
Intrinsic
Value		 
Outstanding and expected to vest at December 31, 2025   15,020,604   $12.51    6.69   $20,007,758 
Granted   
-
   $
-
    -   $
-
 
Cancelled   (125)  $
-
    -   $
-
 
Outstanding at March 31, 2026   15,020,479   $12.51    6.44   $37,924,296 
Options exercisable at March 31, 2026   10,796,790   $16.69    5.48   $16,201,985 
Schedule of Weighted Average fair Value of Options Granted

No options were granted in the three months ended March 31, 2026. For the year ended December 31, 2025, the weighted average fair value of options granted was approximately $1.38 per share, calculated using the Black-Scholes model with the following specific assumptions:

 

  

Three Months Ended

   Year Ended 
   March 31,   December 31, 
   2026   2025 
Risk free interest rate   
     -
%   3.85 to 4.16%
Dividend yield   
-
%   0%
Volatility   
-
%   126.4-134.4%
Expected term (in years)   
-
    6.25 
Schedule of Changes in Outstanding Warrants

A summary of the changes in outstanding warrants during the three months ended March 31, 2026 is as follows:

 

   Number of
Shares		   Weighted
Average
Exercise
Price
Per
Share		 
Outstanding Warrants at December 31, 2025   5,880,085   $2.86 
Granted   4,210,527   $0.001 
Exercised   (2,082,500)  $
-
 
Outstanding at March 31, 2026   8,008,112   $2.10 
Warrants exercisable at March 31, 2026   8,008,112   $2.10 
Schedule of Components of Stock-Based Compensation Expense

The following summarizes the components of stock-based compensation expense which includes, stock options, and warrants in the unaudited consolidated statements of operations for the three months ended March 31, 2026 and 2025 (rounded to nearest $00):

 

   Three Months
Ended
March 31,
2026		   Three Months
Ended
March 31,
2025		 
Research and development  $237,000   $162,100 
General and administrative   719,200    3,410,700 
Total  $956,200   $3,572,800